China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q4 2024 earnings summary

Executive summary

• Achieved revenue of ¥27.62 billion in 2024, up 11.63% year-over-year, with net profit attributable to shareholders of ¥3.37 billion, up 18.05% year-over-year.

• Core CHC (consumer health) business grew 14.13% and prescription drug business grew 15.04% year-over-year.

• Completed major integration of Kunming Pharmaceutical Group and advanced the acquisition of a 28% stake in Tasly, pending shareholder approval.

• Maintained strong cash flow from operations at ¥4.40 billion, up 5.02% year-over-year.

Financial highlights

• Revenue: ¥27.62 billion, up 11.63% year-over-year.

• Net profit attributable to shareholders: ¥3.37 billion, up 18.05% year-over-year.

• Basic and diluted EPS: ¥2.63, up 17.41% and 17.94% year-over-year, respectively.

• Gross margin for CHC business: 60.86%; prescription drugs: 47.51%; Kunming traditional medicine: 64.02%.

• Operating cash flow: ¥4.40 billion, up 5.02% year-over-year.

• Dividend payout ratio: 50.34% of net profit, with total cash dividends of ¥1.70 billion.

Outlook and guidance

• Expects double-digit revenue growth and net profit growth in 2025, with continued focus on innovation, integration of acquired businesses, and digital transformation.

• Plans to invest approximately ¥1 billion in capital expenditures and maintain normal operating capital needs of about ¥2.9 billion.

• Strategic focus on expanding CHC, prescription, and traditional medicine businesses, and further internationalization.